Clinical trials
Immunotherapy clinical trials
Below are recruiting immunotherapy clinical trials, each written for real people, not researchers. We’re tracking 746 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07554846RecruitingPhase 3
Comparing immunotherapy before, during, or after surgery for early-stage lung cancer
This trial compares giving immunotherapy at different times around surgery for stage II-IIIA non-small cell lung cancer. The goal is to find the best time to use this treatment to improve outcomes.
ShanghaiAges 18–75 - NCT07401537RecruitingPhase 2
Comparing two schedules of immunotherapy for advanced triple-negative breast cancer
This trial tests whether giving immunotherapy less often (extended dose intervals) works as well as the standard schedule for people with advanced triple-negative breast cancer who have already completed 6 cycles of first-line treatment. It aims to see if a longer break between doses can be just as effective with fewer hospital visits.
Guangzhou, GuangdongAges 18–70 - NCT06734702RecruitingPhase 3
Immunotherapy before chemo-radiation for advanced lung cancer
This trial tests a new approach for people with stage III lung cancer that cannot be removed with surgery. You would receive immunotherapy (to help your immune system fight cancer) plus chemotherapy first, then standard chemo-radiation, and finally more immunotherapy. The goal is to see if this sequence works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT04286841Recruiting
Immunotherapy before lung surgery for early lung cancer
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
Guangzhou, GuangdongAges 18 years+ - NCT05493267RecruitingPhase 4
Tested immune-cell therapy for drug-resistant tuberculosis
This trial studies an immune-based treatment made from certain T cells (Vγ2Vδ2 T lymphocytes) for multi-drug–resistant tuberculosis (MDR-TB). It may help people whose current drug regimen is not working well or who have limited effective options.
ShanghaiAges 18–65 - NCT04688801Recruiting
Chemo plus immunotherapy after surgery for esophageal cancer
This study looks at adding immunotherapy to standard chemotherapy after surgery for certain esophageal or EG-junction cancers. It may help lower the chance the cancer comes back, for people whose cancer can be fully removed.
Jinan, ShandongAges 25–80 - NCT06241326Recruiting
Immunotherapy for liver cancer study
This trial tests immunotherapy-based combinations for liver cancer. It may help if your doctor thinks this treatment could benefit you.
Nanjing, JiangsuAges 18 years+ - NCT06523478Recruiting
Tonsil injection allergy shots for hay fever
This trial tests a new way to treat allergies by injecting allergy medicine directly into the tonsils. It may help people with hay fever who haven't gotten relief from standard treatments or want to avoid long-term medication.
Wuhan, HubeiAges 5–65 - NCT07475403RecruitingPhase 2
Immunotherapy guided by urine DNA for high risk bladder cancer
This trial tests a new immunotherapy approach for people with a very high risk type of bladder cancer that hasn't spread into the muscle layer. The treatment is guided by a special urine test that looks for tumor DNA, and it may help if surgery cannot remove all the cancer or you choose not to have your bladder removed.
TianjinAges 18 years+ - NCT06849167RecruitingPhase 2
Immunotherapy with low-dose chemoradiation for advanced lung cancer
This trial tests combining immunotherapy with a shorter course of chemoradiation for locally advanced non-small cell lung cancer that hasn't spread. It aims to see if this approach is more effective and tolerable than standard treatment.
BeijingAges 18–70 - NCT06849193Recruiting
Predicting treatment outcomes in advanced bile duct cancer
This study looks at how well current chemotherapy and immunotherapy work for advanced bile duct or gallbladder cancers that cannot be removed by surgery. Researchers will collect data from multiple centers to build a model that helps predict how patients may respond to treatment.
Nanjing, JiangsuAges 18 years+ - NCT05922176Recruiting
Microneedle patch testing to predict allergy treatment response
This study uses a small microneedle patch to collect skin-related samples to help predict how well allergy immunotherapy may work. It includes people with house dust mite allergy and also a healthy control group, so researchers can compare biomarker results.
SeoulAges 19–60 - NCT06926179Recruiting
Immunotherapy before surgery or radiation for lung cancer
This trial tests using immunotherapy before surgery or radiation for non-small cell lung cancer. It looks at how safe and effective this approach is and how it affects survival.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07034326RecruitingPhase 2/Phase 3
Acupuncture plus immunotherapy after lung cancer surgery
This trial explores whether adding electroacupuncture (a gentle needle treatment with mild electric pulses) to standard immunotherapy after lung cancer surgery can help prevent the cancer from coming back. It is designed for people with early-stage non-small cell lung cancer who have already had chemotherapy.
TianjinAges 18–80 - NCT07014202RecruitingPhase 2
Radiation therapy after chemo-immunotherapy for lung cancer
This trial tests whether giving focused radiation to remaining spots of lung cancer (after standard treatment) can help prevent cancer from growing back. It may be an option if you have had 4-6 cycles of chemo plus immunotherapy and still have a few active spots.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06935890RecruitingPhase 4
Long-term effectiveness of jack jumper ant venom therapy
This study checks how well venom immunotherapy for jack jumper ant allergy works years after treatment ends. If you finished 3–5 years of treatment and stopped 1.5 to 5 years ago, you may be able to help.
Adelaide, South AustraliaAges 18 years+ - NCT06767306RecruitingPhase 2
SBRT radiation plus immunotherapy for limited spread melanoma
This trial tests if combining targeted radiation (SBRT) with standard immunotherapy works better for melanoma that has spread to a few spots in the body (but not the brain). It is for people who have not yet had treatment for their current spread.
Westmead, New South WalesAges 18 years+ - NCT06676449RecruitingPhase 3
A study on radiation-sparing treatment for advanced esophageal cancer
This trial tests a new approach for advanced esophageal cancer that combines targeted radiation, immunotherapy, and chemotherapy. It aims to see if skipping radiation to certain lymph nodes can improve outcomes while reducing side effects.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06624644RecruitingPhase 2/Phase 3
LNS8801 with or without pembrolizumab for advanced melanoma
This trial tests a new drug called LNS8801, alone or with pembrolizumab, for people with advanced melanoma that has stopped responding to prior treatments, especially anti-PD-1 therapy.
Newport Beach, CaliforniaAges 18 years+ - NCT06467994RecruitingPhase 2
Boiled cashew nut therapy for children with cashew allergy
This trial tests whether a specially boiled cashew nut can help children with cashew allergy eat cashews without a reaction. It is for children ages 2 to 17 with a confirmed cashew allergy, and it avoids other serious health conditions.
Hong KongAges 2–17 - NCT06197776Recruiting
Predicting treatment success for advanced nasopharyngeal cancer
This study uses advanced testing (multi-omics) to predict if combining chemoradiation with immunotherapy works better for nasopharyngeal cancer that has returned or spread. It aims to find the right treatment for each person.
Guangzhou, GuangdongAges 18–70 - NCT07625527RecruitingPhase 2
Stopping immunotherapy after bladder cancer disappears
This trial tests whether it's safe to stop immunotherapy once bladder cancer is no longer visible, instead of continuing it for a longer time. It aims to find out if stopping treatment early can reduce side effects while keeping the cancer from coming back.
TianjinAges 18 years+ - NCT05354375RecruitingPhase 1
PSMA-targeted CAR-T cell therapy for resistant prostate cancer
This Phase 1 study tests whether lab-made immune cells (CAR-T) that target PSMA can treat prostate cancer that keeps growing despite hormone treatment. It may help people whose disease no longer responds to standard endocrine (hormone-blocking) therapy.
Xuzhou, JiangsuAges 18–75 - NCT05527795Recruiting
Study features that predict benefit from extra immunotherapy in melanoma
This study looks for lab and tumor features that may help predict who benefits from follow-up (adjuvant) immunotherapy after surgery for melanoma. Your past treatment and tumor samples may be used to improve future treatment decisions.
Pierre-BéniteAges 18 years+
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunotherapy?
- Yes. Clin2 currently lists 746 recruiting immunotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.